Cell therapy weekly: ReLive Biotechnologies completes asset purchase of Co.Don AG

This week: Researchers develop a tool to automate reporting hematopoietic cell transplant engraftment, Forge Biologics expands its leadership team and ReLive Biotechnologies has completed its asset purchase of biotech company Co.Don AG. The news highlights: Researchers automate reporting of hematopoietic cell transplant engraftment to reduce errors Forge Biologics announces leadership team expansion ReLive Biotechnologies completes asset purchase of Co.Don AG. Researchers automate reporting of hematopoietic cell transplant engraftment to reduce errors Researchers at the Children’s Hospital of Philadelphia (PA, USA) have developed an automated computational tool to improve the accuracy of engraftment calculations following hematopoietic stem cell (HSC) transplant. HSC...